Go Pro
NASDAQ:XOMAO

XOMA (XOMAO) Stock Price, News & Analysis

XOMA logo
$25.00 0.00 (0.00%)
As of 08/7/2026

About XOMA Stock (NASDAQ:XOMAO)

Advanced

Key Stats

Today's Range
$25.00
$25.00
50-Day Range
$24.96
$25.47
52-Week Range
$24.86
$26.40
Volume
N/A
Average Volume
4,279 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
8.36%
Price Target
N/A
Consensus Rating
N/A

Company Overview

XOMA Corporation is a clinical-stage biotechnology company specializing in the discovery and development of therapeutic antibodies. The company applies its proprietary protein engineering and antibody optimization platform to generate novel drug candidates targeting autoimmune, inflammatory and metabolic diseases. XOMA’s scientific expertise spans antibody discovery, engineering, in vitro and in vivo testing, and early‐stage clinical development.

In addition to advancing its own pipeline of antibody candidates, XOMA collaborates with pharmaceutical and biotechnology partners to provide research and development services. These collaborations leverage XOMA’s capabilities in protein expression, assay development, and manufacturing process design, enabling partner companies to accelerate preclinical and early clinical programs. The company’s business model combines internal drug development with fee‐based service agreements and licensing arrangements.

Founded in 1979 and headquartered in Berkeley, California, XOMA was among the early pioneers in monoclonal antibody technology. Over four decades, the company has played a role in advancing antibody therapeutics through both in‐house research and strategic partnerships. While based in the United States, XOMA’s collaborative network extends to Europe and other regions, reflecting its commitment to global drug development efforts.

AI Generated. May Contain Errors.

Receive XOMAO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

XOMAO Stock News Headlines

FDA Clears This Under-$5 Biotech for Phase 2 Clinical Trial
A NASDAQ-listed biotech just cleared a major FDA milestone. Its lead therapy, Lucid-MS, has been cleared for Phase 2 trials in progressive multiple sclerosis. Unlike existing treatments that suppress the immune system, Lucid-MS is designed to protect myelin. In pre-clinical models, it led to movement recovery including walking. Independent research projects peak annual sales up to 5 billion dollars, yet shares still trade under 5 dollars.tc pixel
See More Headlines

XOMAO Stock Analysis - Frequently Asked Questions

XOMA's stock was trading at $25.56 at the start of the year. Since then, XOMAO shares have decreased by 2.2% and is now trading at $25.00.

Shares of XOMAO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Record date for 7/14 Dividend
7/02/2026
Ex-Dividend for 7/14 Dividend
7/02/2026
Dividend Payable
7/14/2026
Today
8/10/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:XOMAO
CIK
791908
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$7.65 million
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:XOMAO) was last updated on 8/10/2026 by MarketBeat.com Staff.
From Our Partners